Genome-editing technology has broad potential for treating cancers
the ONA take:
Researchers from the Walter and Eliza Hall Institute, in Melbourne, Australia, have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.
Using the technology, called CRISPR, the researchers were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival.
The technology can directly target any gene in a person’s genome, thereby overcoming many problems commonly encountered in drug development.
The system works by efficiently locating and targeting a particular gene. It can introduce mutations that make the genome nonfunctional, or introduce changes that make mutated genes function normally again.
The researchers report that the technology has a wide range of potential in terms of drug development for treating genetic diseases such as cancer.
Researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|